ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / MRVI
SDGR (53) ZYME (50) SEPN (63) SRPT (27) ⌘ Pro Terminal β†’

Maravai LifeSciences Holdings Inc. (Class A) (MRVI) β€” RQD Stock Rating Cockpit

$7.81 -7.68% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.69

Maravai LifeSciences Holdings Inc. (Class A) (MRVI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (37/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $2.03B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRVI Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is MRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ: MRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.81 (-7.68% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MRVI ranks #529 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does MRVI compare to SDGR and ZYME in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRVI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 18.3%, and ROIC of -35.0%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, MRVI leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRVI?
β–Ό

Per MRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001823239), Maravai LifeSciences Holdings Inc. (Class A) generated $185.7M in revenue (-28.3% YoY), -$130.8M in net income, and -$70.7M in free cash flow against $770.6M in total assets and $286.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.69 (-1.57%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (37/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (5)Whales (13)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$10 Bull$7 Base$6 Bear
πŸ“¬ FREE MRVI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for MRVI)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
πŸ” WHY MRVI SCORES 37/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.04 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
29
Grade E$6.53+10.3% Next Q
Q2 (-2Q)
32
Grade E$7.20+14.7% Next Q
Q3 (-1Q)
34
Grade E$8.26-5.4% Next Q
Current
37
Grade D-$7.81-8.1% Hist 90D Ξ±
Trajectory: E (29) β†’ D- (37)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a MRVI Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While MRVI currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.48) and Max Pain ($8.20) forces dealer call-delta covering toward $9.89.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRVIβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œMRVI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
52.230 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.04>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE77% OF RANGE
L: $3$7.81H: $9
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MRVI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 18.3% gross margin and -3.22% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 3.04 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

16/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like MRVI
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRVI)

  • βœ“Walkthrough of MRVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
MRVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +106.07%πŸ“ WEDGE COMPRESSION COIL
2026-11-03O $8.46H $8.46L $7.81C $7.81VOL 1.70M
RES: $8.57SUP: $6.60SMA50: $7.48SMA200: $5.28
$9.86$8.04$6.23$4.41$2.60RES $8.57SUP $6.60$7.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ MRVI Butterfly Map β†’ + Track MRVI β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -28.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MRVI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for MRVI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRVI)

Health Care Rank #529 of 1016 βš”οΈ SDGR vs MRVI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (MRVI vs. SDGR, ZYME, SEPN, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Maravai LifeSciences Holdings Inc. (Class A) (MRVI) ranks #529 by composite RQD confidence (37/100, grade D-) and #253 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, MRVI leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and β€” gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with MRVI at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MRVI ACTIVE
Maravai LifeSciences Holdings Inc. (Class A)
D- 37/100 β€” 18.3% -35.0% -7.68% $2.03B Benchmark Subject
SDGR
Schrodinger Inc.
D+ 53/100 β€” 55.7% -35.0% -9.50% $2.03B /sdgr-vs-mrvi β†’
ZYME
Zymeworks Inc.
D 50/100 β€” β€” -32.2% -0.35% $2.02B /zyme-vs-mrvi β†’
SEPN
Septerna Inc.
C 63/100 β€” β€” -20.7% -2.72% $2.05B /sepn-vs-mrvi β†’
SRPT
Sarepta Therapeutics Inc.
E 27/100 β€” 96.0% -35.0% -3.17% $1.97B /srpt-vs-mrvi β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001823239

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maravai LifeSciences Holdings Inc. (Class A) (MRVI) reported GAAP revenue of $185.7M (-28.3% vs. FY2024 revenue of $259.2M , and -35.7% cumulative change since FY2023) , GAAP net income of -$130.8M, operating cash flow of -$57.6M, and free cash flow of -$70.7M (-218.7% YoY). On the balance sheet, MRVI closed FY2025 with $770.6M in total assets against $286.3M in total debt (Altman Z-Score: 3.04, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $185.7M -$130.8M -$57.6M -$70.7M $770.6M $286.3M
FY2024 (FY) 2024-12-31 $259.2M -$144.8M $7.5M -$22.2M $1.01B $290.5M
FY2023 (FY) 2023-12-31 $288.9M -$138.4M $126.2M $126.2M β€” β€”

3. MRVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ: MRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.81 (-7.68% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MRVI ranks #529 in composite RQD confidence.

How does MRVI compare to SDGR and ZYME in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRVI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 18.3%, and ROIC of -35.0%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, MRVI leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRVI?

Per MRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001823239), Maravai LifeSciences Holdings Inc. (Class A) generated $185.7M in revenue (-28.3% YoY), -$130.8M in net income, and -$70.7M in free cash flow against $770.6M in total assets and $286.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRVI trading relative to its 50-day, 200-day, and 52-week technical levels?

MRVI last traded at $7.81 (-7.68% on volume of 1,703,957 shares), positioning the stock +4.41% above its 50-day simple moving average ($7.48) and +47.92% above its 200-day simple moving average ($5.28). Across its 52-week range of $2.55 to $9.42, MRVI sits at the 76.6% percentile with a 14-day RSI of 52.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($6.83 to $8.79).

MRVI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell MRVI stock right now?

Maravai LifeSciences Holdings Inc. (Class A) (MRVI) currently earns a Roarable Rating of D- (Sell β€” SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MRVI's 12-month price target and RQD AI Jury consensus?

MRVI's 12-month base price target is $7.07 (range $5.51 to $9.89), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MRVI RQD Cockpit MRVI 12M Forecast MRVI Earnings & Move MRVI Dividends & DRIP MRVI Insiders & 13F MRVI Whale Options MRVI Profit Sankey MRVI News & Why
ROARABLE RATING BRIEF β€’ RQD 37/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

MRVI β€” Maravai LifeSciences Holdings Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 40 out of 100, a letter grade of D-, with the verdict label "Roarable Sell β€” Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The five pillars are:

  • Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -3.22%. For a prospective investor, this is the weakest signal: the business is currently not generating a return on invested capital or positive free cash flow relative to its market value.
  • Whale 13F Flow: 16 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and suggests some sophisticated-holder interest, though the holder detail itself is not available in source data.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider-side conviction signals in the source data.
  • Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is in line with broad market moves, and the low score reflects limited regime-fit advantage.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z of 3.04, a Piotroski F of 3/9, and a Debt/Equity of 1.35. The Z-score sits in a range the rating treats as moderately stable, but the weak Piotroski score and elevated leverage limit the pillar.

Taken together, the rating frames a stock where institutional interest is comparatively supportive, but operating cash generation, insider signals, and balance sheet quality are weak. Upside drivers would need to come from a turn in operating economics; the rating does not identify one in the source data. Valuation is difficult to assess directly because earnings-based multiples are not available in source data, and the negative ROIC and FCF yield mean the price is not supported by current cash generation per the rating's own inputs.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$185.7M$-215.3M$-130.8MN/A$-70.7M$216.9M$286.3M
FY 2024$259.2M$-235.6M$-144.8MN/A$-22.2M$322.4M$290.5M
FY 2023$288.9M$-31.6M$-138.4MN/A$126.2MN/AN/A

Per the SEC financials, revenue declined from $288.9M (FY 2023) to $259.2M (FY 2024) to $185.7M (FY 2025), while net losses were reported in every period shown. Per the market data, gross margin is 18.3%, operating margin is -60%, and net margin is -60%, with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 3.04 and the Piotroski F-Score is 3/9. Per the SEC financials, cash declined from $322.4M (FY 2024) to $216.9M (FY 2025) while debt was $286.3M, and the Roarable RQD rating reports a Debt/Equity of 1.35.

Recent Catalysts & News Wire Analysis

Six news items are listed, all relating to MRVI, with publication timestamps between roughly 1 and 15 hours before the data date. Five are tagged as market wire (yellow) and one as risk watch (red). The headlines reported are:

  • A Yahoo! Finance Canada stock price and quote page (market wire).
  • A report that TD Cowen initiated coverage with a buy rating (market wire, per Investing.com).
  • A Yahoo Finance Australia stock price page (market wire).
  • A Simply Wall St stock analysis page (market wire).
  • A Simply Wall St article on the stock dropping and what drove the move (risk watch).
  • A Yahoo Finance article questioning the value of the stock's recovery (market wire).

The TD Cowen buy initiation is the only item with a directional analyst signal. The risk watch item signals a price decline without a stated cause in the source data. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals.

Open Questions

  • What are the company's products and customer base, and what drives the revenue decline from $288.9M to $185.7M across the reported periods?
  • What is the path to positive operating income and free cash flow, given operating margin of -60% and FCF of $-70.7M in FY 2025?
  • How does the company plan to address the decline in cash from $322.4M to $216.9M against debt of $286.3M, and what is the debt maturity profile?
  • What is the identity and size of the institutional holders behind the Whale 13F Flow pillar, and are their positions increasing or decreasing?
  • What specific event drove the risk-watch price decline reported in the recent news, and does it relate to fundamentals or sentiment?

MRVI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Maravai LifeSciences Holdings Inc. (Class A) (MRVI) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to MRVI Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRVI Bull vs. Bear Conversation Board β€” What's Your Call at $7.81?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRVI 🐻 67% BEARISH CONVICTION
1. Pick Your Side on MRVI:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.44 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is MRVI (D- β€’ RQD 40/100) a Buy at $8.46?

Welcome to the MRVI (Maravai LifeSciences Holdings Inc. (Class A)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.11 (-16.0%)
Spot @ $8.46

Pump the brakes on MRVI β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MRVI, but look at what you are paying: current EV/EBITDA multiples with 18.3% gross margins. Unless Maravai LifeSciences Holdings Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $9.64 (+13.9%)
Spot @ $8.46

MRVI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MRVI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.46 (52-wk range $2.55 - $9.42), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%